2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Leukemia
37
Burkitt Lymphoma
13
Lymphoma
9
Leukemia, Biphenotypic, Acute
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
4
Leukemia, Myelomonocytic, Chronic
4
Anemia, Refractory, with Excess of Blasts
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Myeloproliferative Disorders
3
Leukemia, Monocytic, Acute
3
Down Syndrome
3
Recurrence
2
Neutropenia
2
Neoplasms
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Promyelocytic, Acute
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Dendritic Cell Sarcoma, Interdigitating
2
Brain Neoplasms
2
Anemia, Refractory
2
Thrombocytopenia
1
Optic Nerve Glioma
1
Lymphoma, T-Cell
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
99
Fluorouracil
90
Capecitabine
86
Radiotherapy
81
Dexamethasone
81
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Drug Therapy
65
Leucovorin
64
Cetuximab
60
Erlotinib Hydrochloride
56
atezolizumab
53
Sorafenib
53
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Thioguanine
×
Clear all
NCT06351306
2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2
Withdrawn
NCT02912676
2020-04-15
TEAM
Rigshospitalet, Denmark
Phase 1/2
Completed
30 enrolled